Novartis highlights benefits of Mayzent in MS
New data showing the benefits of Novartis' Mayzent (siponimod) in patients with secondary progressive multiple sclerosis (SPMS) have been published in the April supp...
IPI was established by professionals with over 30 years of experience in the Pharmaceutical and Life sciences publishing sectors. Peer-Reviewed, Contemporary, Authoritative